Emergency Medicine Cases – Where the Experts Keep You in the Know. For complete episodes please visit emergencymedicinecases.com
Stephen V. Liu, MD - Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer Care
Manage episode 333465427 series 103449
By PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is performed, many patients are not receiving optimally matched targeted therapy based on their tumor type. This PeerView educational video based on a recent live event and developed in collaboration with the LUNGevity Foundation brings leading lung cancer experts together to go beyond the basics and help navigate the increasing complexity of biomarker testing and targeted therapy in lung cancer. Expert discussions are framed with patient perspectives and illustrative case scenarios to highlight strategies for improving team-based collaboration, patient engagement, health equity, and biomarker-informed management plans to provide the best possible care to all patients. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of NSCLC and mechanisms of action, efficacy, and safety of targeted therapies for established, new, and emerging molecular alterations in NSCLC, Apply current guidelines and best practices for biomarker testing to help inform targeted treatment decisions for patients with NSCLC, Integrate targeted therapies into individualized treatment plans for eligible patients with NSCLC in clinical practice or clinical trials, considering biomarker status; current evidence and guidelines; multidisciplinary perspectives; and patient needs, values, and preferences, Implement multidisciplinary and patient-centric approaches to ensure timely and accurate diagnosis, appropriate biomarker testing, individualized treatment, and equitable care of all patients with NSCLC.